Revisiting sensitivity of senescent cells to BH3 mimetics

Nadine Martin; Anda Huna; Athanasios Tsalikis; David Bernard

doi:10.1016/j.tips.2024.01.002

Revisiting sensitivity of senescent cells to BH3 mimetics

Trends Pharmacol Sci. 2024 Apr;45(4):287-289. doi: 10.1016/j.tips.2024.01.002. Epub 2024 Jan 20.

Authors

Nadine Martin¹, Anda Huna², Athanasios Tsalikis², David Bernard³

Affiliations

¹ Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France; Equipe Labellisée la Ligue Contre le Cancer, Lyon, France. Electronic address: nadine.martin@lyon.unicancer.fr.
² Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France; Equipe Labellisée la Ligue Contre le Cancer, Lyon, France.
³ Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France; Equipe Labellisée la Ligue Contre le Cancer, Lyon, France. Electronic address: david.bernard@lyon.unicancer.fr.

PMID: 38245492
DOI: 10.1016/j.tips.2024.01.002

Abstract

B cell leukemia/lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics were reported to selectively kill senescent cells and improve age-related diseases. Defining why these cells show increased sensitivity to these molecules will help to identify new pharmacological compounds with senolytic activity. Here, we discuss how recent research findings provide new clues to understand this vulnerability.

Keywords: BCL2; MOMP; aging; cellular senescence; senolytics.

MeSH terms

Cellular Senescence*
Humans